Tag Archive for: target action dates

Thursday, the FDA pushed back its target action date by three months for Daiichi Sankyo’s investigational acute myeloid leukemia (AML) drug quizartinib, citing updates to the proposed Risk Evaluation and Mitigation Strategies (REMS).

The U.S. Food and Drug Administration has a handful of PDUFA dates over the next two weeks.